SavedAdd your journal

Journals / Bozok Veterinary Sciences / 2025 / Cilt: 6 Sayı: 2

Preliminary Diagnosis of Cutaneous Lupus Erythematosus in a Dog and Treatment with Inhaled Methylene Blue: A Case Presentation Related to the Permeable Intestine-Autoimmunity Cascade

Bir Köpekte Kutanöz Lupus Eritematozis Ön Tanısı ve İnhaler Metilen Mavisi ile Sağaltım: Geçirgen Bağırsak-Otoimmunite Kaskadına İlişkin Olgu Takdimi

Kerem Ural(AYDIN ADNAN MENDERES UNIVERSITY)0000-0003-1867-7143
Tahir Özalp(Aydın Adnan Menderes Üniversitesi)0000-0002-9873-0364
Serdar Paşa(AYDIN ADNAN MENDERES ÜNİVERSİTESİ)0000-0003-4957-9263
Hasan Erdoğan(AYDIN ADNAN MENDERES ÜNİVERSİTESİ)0000-0001-5141-5108
Songül Erdoğan(AYDIN ADNAN MENDERES ÜNİVERSİTESİ)0000-0002-7833-5519
Umut Coşkun(AYDIN ADNAN MENDERES ÜNİVERSİTESİ)0000-0002-2053-9340
Pages
99–102
Publication Date
2025-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The inhalation route of methylene blue administration supports clinical improvement and may serve as a significant alternative therapeutic option in the treatment of cutaneous lupus erythematosus in dogs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this case, the contribution of inhaled methylene blue treatment to clinical improvement was evaluated in a dog suspected of having cutaneous lupus erythematosus.
📊
Key Findings & Data:A 5-year-old, female, mixed-breed dog was presented to our clinic for the treatment of an ulcerative lesion on the nasal planum.
💡
Conclusion & Impact:The inhalation route of methylene blue administration supports clinical improvement and may serve as a significant alternative therapeutic option in the treatment of cutaneous lupus erythematosus in dogs.
🔬Design:Olgu Sunumu
📍Scope:Comprehensive Sample
⚙️Variables:Köpek · Kutanöz lupus eritematozis · Metilen mavisi

Abstract

In this case, the contribution of inhaled methylene blue treatment to clinical improvement was evaluated in a dog suspected of having cutaneous lupus erythematosus. A 5-year-old, female, mixed-breed dog was presented to our clinic for the treatment of an ulcerative lesion on the nasal planum. Following clinical evaluations, the dog was diagnosed with cutaneous lupus erythematosus and treated with inhaled methylene blue in combination with oral Argivit Classic Syrup as supportive therapy. Additionally, the biomarkers zonulin and diamine oxidase were analyzed to assess the presence of leaky gut syndrome. On the 15th day after the treatment, clinical re-evaluation revealed that the lesions had resolved, zonulin levels indicating leaky gut syndrome had decreased, and diamine oxidase levels had increased. The inhalation route of methylene blue administration supports clinical improvement and may serve as a significant alternative therapeutic option in the treatment of cutaneous lupus erythematosus in dogs.

Özet

Olgumuzda kutanöz lupus eritematozus şüpheli köpeğin inhaler yolla metilen mavisi ile sağaltımının klinik olarak iyileşmeye katkısı değerlendirilmiştir. 5 yaşlı, dişi ve melez ırk köpek burun planumundaki ülserli lezyonun sağaltımı için kliniğimize başvurdu. Yapılan incelemeler sonucunda klinik olarak kutanöz lupus eritematozus tanısı konulan köpeğe inhaler metilen mavisi ve destekleyici olarak oral Argivit Classic Şurup uygulandı. Ayrıca Geçirken bağırsak sendromunun belirlenmesi için zonulin ve diaminooksidaz biyobelirteçlerinin analizleri gerçekleştirildi. Sağaltım sonrası 15. günde yapılan kontroller sonucunda hastadaki lezyonların klinik olarak iyileştiği, geçirgen bağırsak sendromunu gösteren zonulin seviyelerinin azaldığı ve diaminooksidaz seviyelerinde ise artış görüldüğü tespit edildi. Metilen mavisinin inhaler uygulaması köpeklerde kutanöz lupus eritematozus sağaltımında önemli bir alternatif ajan olarak klinik iyileşmeyi desteklemektedir.

🔖

Cite This Article

Ural, K., Özalp, T., Paşa, S., Erdoğan, H., Erdoğan, S., Coşkun, U. (2025). Preliminary Diagnosis of Cutaneous Lupus Erythematosus in a Dog and Treatment with Inhaled Methylene Blue: A Case Presentation Related to the Permeable Intestine-Autoimmunity Cascade. Bozok Veterinary Sciences, Cilt: 6 Sayı: 2, 99–102. https://doi.org/10.58833/bozokvetsci.1741870

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (42)

  1. Sontheimer RD. The lexicon of cutaneous lupus erythematosus – a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84–95.
  2. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. Journal of Autoimmunity 2014; 48–49: 14–19.
  3. Jackson HA, Olivry T. Ulcerative dermatosis of the Shetland sheepdog and rough collie dog may represent a novel vesicular variant of cutaneous lupus erythematosus. Vet Dermatol 2001; 12(1): 19–28. 4. Jackson HA, Olivry T, Berget F, Dunston SM, Bonnefort C et al. Immunopathology of vesicular cutaneous lupus erythematosus in the rough collie and Shetland sheepdog: a canine homologue of subacute cutaneous lupus erythematosus in humans. Vet Dermatol 2004; 15(4): 230–239.
  4. Gibson IR, Barnes J. Vesicular cutaneous lupus erythematosus in a Border Collie in New Zealand. New Zealand Veterinary Journal 2011; 59(3): 153.
  5. Lehner GM, Liner M. A case of vesicular cutaneous lupus erythematosus in a Border Collie successfully treated with topical tacrolimus and nicotinamide-tetracycline. Vet Dermatol 2013; 24: 639–e160.
  6. Jackson HA. Eleven cases of vesicular cutaneous lupus erythematosus in Shetland sheepdogs and rough collies: clinical management and prognosis. Vet Dermatol 2004; 15: 37–41.
  7. Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nature Reviews Rheumatology 2019; 15: 519–532.
  8. Griffin CE, Stannard AA, Ihrke PJ, Ardans AA, Cello RM et al. Canine discoid lupus erythematosus. Vet Immunol Immunopathol 1979; 1: 79–87.
  9. Ziemer M, Milkova L, Kunz M. Lupus erythematosus. Part II: clinical picture, diagnosis and treatment. J Dtsch Dermatol Ges 2014; 12: 285–301; quiz 302.
  10. Kurtdede A, Ural K, Guzel M, Gazyagci S, Arikok A. Cutaneous lupus erythematosus in a dog. Revue Med Vet 2003; 154(10): 587–590.
  11. Font A, Bardagi M, Mascort J, Fondevila D. Treatment with oral cyclosporin A of a case of vesicular cutaneous lupus erythematosus in a rough collie. Vet Dermatol 2006; 17: 440–442.
  12. Banovic F, Olivry T, Linder KE, Tobias JR. Pathology in practice. Psoriasiform lichenoid dermatitis. J Am Vet Med Assoc 2014; 245: 1237–1239.
  13. Kelner MJ, Bagnell R, Hale B, Alexander NM. Potential of methylene blue to block oxygen radical generation in reperfusion injury. In: Oxygen radicals in biology and medicine. Springer, Boston; 1988: 895–898.
  14. Wen Y, Li W, Poteet EC, Xie L., Tan C et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. The Journal of Biological Chemistry 2011; 286: 16504–16515.
  15. Visarius TM, Stucki JW, Lauterburg BH. Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Letters 1997; 412: 157–160.
  16. Swerdlow RH. Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals 2009; 2: 150–167.
  17. Ural K, Erdoğan H, Erdoğan S, Paşa S, Sungur A et al. Nebulized methylene blue as an anti-pruritic treatment modality in dogs with atopic dermatitis. Bozok Veterinary Sciences 2025; 6(1): 41–45.
  18. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clinics in Dermatology 2006; 24: 348–362.
  19. Olivry T, Alhaidari Z, Carlotti DN, Guaguère E, Régnier A et al. Le lupus érythémateux discoïde du chien: à propos de 22 observations (discoid lupus erythematosus in the dog: 22 cases). Prat Med Chir Anim Comp 1987; 22: 205–214.
  20. Scott DW, Walton DK, Slater MR, Smith CA, Lewis RM. Immune-mediated dermatoses in domestic animals: ten years after - part II. Compendium on Continuing Education for the Practicing Veterinarian 1987; 9: 539–551.
  21. Ahmad R, Sorrell MF, Batra SK, Dhawan P, Singh AB. Gut permeability and mucosal inflammation: bad, good or context dependent. Mucosal Immunol 2017; 10: 307–317.
  22. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol 2017; 8: 598.
  23. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nature Reviews Immunology 2017; 17: 219–232.
  24. Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 2015; 8: 5153–5160.
  25. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F et al. Alterations of the human gut microbiome in multiple sclerosis. Nature Communication 2016; 7: 12015.
  26. Hevia A, Milani C, López P, Cuervo A, Arboleya S et al. Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 2014; 5: 1548–1562.
  27. Sorini C, Cosorich I, Lo Conte M, De Giorgi L, Facciotti F et al. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. Proc Natl Acad Sci USA 2019; 116: 15140–15149.
  28. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 2002; 123(5): 1607–1615.
  29. Thomas KE, Sapone A, Fasano A, Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in celiac disease. The Journal of Immunol 2006; 176(4): 2512–2521.
  30. Fasano A, Not T, Wang W, Uzzau S, Berti I et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355(9214): 1518–1519.
  31. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. Journal of Cell Science 2000; 113(24): 4435–4440.
  32. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004; 113: 427–437.
  33. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 179–189.
  34. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology 2012; 96: 32–45.
  35. Yang SH, Li W, Sumien N, Forster M, Simpkins JW et al. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: methylene blue connects the dots. Progress in Neurobiology 2017; 157: 273–291.
  36. Salaris SC, Babbs CF, Voorhees WD. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase: a potential new drug for the attenuation of ischemia/reperfusion injury. Biochemical Pharmacology 1991; 42: 499–506.
  37. Alberts B, Johnson A, Lewis J, Raff M, Roberts K et al. Molecular Biology of the Cell. Fourth Edition. New York: Garland Science, 2002.
  38. Yu R, Lendahl U, Nistér M, Zhao J. Regulation of mammalian mitochondrial dynamics: opportunities and challenges. Frontiers in Endocrinology 2020; 11: 374.
  39. Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Ośko I, Kucia M et al. Mitochondrial oxidative stress—a causative factor and therapeutic target in many diseases. International Journal of Molecular Sciences 2021; 22: 13384.
  40. Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: central and peripheral mode of action. Experimental Neurology 2016; 277: 58–67.
  41. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochemical Pharmacology 1993; 45: 367–374.
  42. Patel JD, Krupka T, Anderson JM. iNOS-mediated generation of reactive oxygen and nitrogen species by biomaterial-adherent neutrophils. Journal of Biomedical Materials Research A 2007; 80A: 381–390.